Stratec SESTU:SBS +0.12%61 EBITDA Margin % is 8.27% as of Mar. 2026, which is 57% below its 10-year median of 19.19. GuruFocus rates STU:SBS with a GF Score™ of 61/100 and a GF Value™ of €32.11 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Stratec SE ranks better than 60.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Stratec SE's EBITDA for the
three
months ended in Mar. 2026 was €4.4 Mil. Stratec SE's Revenue for the
three
months ended in Mar. 2026 was €53.4 Mil. Therefore, Stratec SE's EBITDA margin for the quarter that ended in Mar. 2026 was 8.27%.
Stratec SE (STU:SBS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Stratec SE EBITDA Margin % Related Terms
Stratec SE EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Stratec SE's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:SBS vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Stratec SE's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stratec SE EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Stratec SE's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stratec SE (STU:SBS) has a EBITDA Margin % of 8.27% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Stratec SE and its competitors. This is 57% below median its historical median of 19.19. Over the past decade, Stratec SE's EBITDA Margin % has ranged from 12.41 to 23.28. According to the industry distribution chart, Stratec SE ranks #325 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 39.8%.
Is Stratec SE's EBITDA Margin % too high?
Stratec SE's current EBITDA Margin % of 8.27% is 57% below median its 10-year median of 19.19. Over the past 10 years, this metric has ranged from a low of 12.41 to a high of 23.28. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Stratec SE's value of 8.27% is 10.6% above this industry median. Based on the distribution chart, Stratec SE ranks #325 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Stratec SE has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stratec SE's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Stratec SE ranks #325 out of 816 companies for EBITDA Margin %. This puts Stratec SE in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Stratec SE's value of 8.27% is 10.6% above this benchmark. Historically, Stratec SE's own EBITDA Margin % has ranged from 12.41 to 23.28 over the past decade. While the company's 10-year median is 19.19 vs. the industry median of 7.48, Stratec SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stratec SE's current EBITDA Margin % of 8.27% is 10.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Stratec SE and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stratec SE's current EBITDA Margin % is 8.27%, which is 57% below median its own 10-year median of 19.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stratec SE stock overvalued right now?
Based on GuruFocus' analysis, Stratec SE (STU:SBS) is currently considered Significantly Undervalued. The stock's GF Value™ is €32.11, compared to a current price of €17.20 — trading 46.4% below its estimated fair value. The current EBITDA Margin % is 8.27%, which is 57% below median its 10-year median of 19.19 and 10.6% above the Medical Devices & Instruments industry median of 7.48. Stratec SE's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Stratec SE (STU:SBS), the current EBITDA Margin % is 8.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stratec SE (STU:SBS) Overvalued in 2026?
Based on GuruFocus' analysis, Stratec SE stock appears to be undervalued.
The current stock price of €17.20 is trading 46.4% below its estimated GF Value™ of €32.11.
GuruFocus considers Stratec SE to be Significantly Undervalued.
Key valuation signals for STU:SBS:
EBITDA Margin %: 8.27% (57% below median its 10-year median of 19.19)
GF Value™: €32.11 vs. price of €17.20 (46.4% below fair value)
Industry Position: 10.6% above the Medical Devices & Instruments median (#325 of 816)
No single metric tells the full story. See the STU:SBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stratec SE designs and manufactures automation solutions for regulated laboratory markets. STRATEC acts as an OEM partner to players in the in-vitro diagnostics and life sciences markets. The Group's product range includes both hardware solutions, software solutions, and related consumables, as well as independently marketed consumables. These products are mostly combined into fully integrated system solutions and often receive market approval together with partners' reagents.
61GF Score
Get the complete analysis for STU:SBS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:SBS has been successfully added to your 
